Loading organizations...
§ Venture Capital · Montréal, QC, Canada
T2C2/Bio operates as a venture capital firm dedicated to early-stage life science companies. Its strategy involves identifying and supporting university spin-outs, aiming to commercialize academic research. The firm provides capital and strategic guidance, translating scientific breakthroughs from Canadian institutions into market solutions.
Dr. Maha Katabi launched her venture capital career with the firm in 1999. With a PhD in Pharmacology and BSc in Biology, Dr. Katabi offered a scientific lens, discerning commercial potential within university research. This insight guided T2C2/Bio to focus on research-intensive, seed-stage companies, bridging Canadian academia and biotechnology commercialization.
T2C2/Bio backs university researchers and entrepreneurial scientists developing novel life science solutions in Canada. The firm’s vision is to cultivate a robust domestic biotechnology industry by nurturing start-ups from foundational stages. This support facilitates maturation, fostering healthcare advancements and generating economic value through innovation.
T2C2/Bio has 1 tracked investment across 1 company. The latest tracked deal is $10.1M Other Equity in PhageTech in March 2002.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 15, 2002 | PhageTech | $10.1M Other Equity | CDP Capital Technology Ventures | Genechem, MDS Capital, Seaflower Ventures |